NICE says no to Celgene's myeloma drug Imnovid; Sucampo, Takeda extend Amitiza pact;

> The U.K.'s cost-effectiveness watchdog has issued preliminary draft guidance not recommending Celgene's ($CELG) multiple myeloma treatment Imnovid. More

> Sucampo and Takeda have extended their licensing agreement for constipation drug Amitiza. Release

> ViiV Healthcare has won approval for HIV pill Triumeq in Canada. Release

> Scotland has recommended Novartis' ($NVS) Gilenya for patients with a severe form of relapsing multiple sclerosis. Report

> Retrophin has agreed to divest ketamine, Syntocinon Nasal Spray, and Vecamyl to Turing Pharmaceuticals. Release

And Finally... Pfizer ($PFE) has joined up with leaders in the breast cancer community to expand the breast cancer dialogue to include metastatic breast cancer. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.